

Overcoming chemotherapy resistance Rights Issue 2020



Disclaimer

This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "Presentation"), has been prepared by Scandion Oncology A/S ("Scandion Oncology" or the "Company"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.

This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction and the Presentation does not constitute, and should not be considered as, a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 and do not constitute an offer to acquire securities in the Company. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The Company is currently preparing a prospectus which is expected to be approved by and registered with the Swedish Financial Supervisory Authority (the "SFSA") around 24 November 2020 (the "Prospectus") relating to a rights issue of shares of approximately SEK 236 million resolved upon by the Company's board of directors on 16 November (the "rights issue"). The Prospectus presents risks connected to an investment in the Company, and prospective investors in the rights issue are advised to read the Prospectus in its entirety before making a decision whether to invest in the Company. The expected approval from the SFSA of the Prospectus should not be understood as an endorsement of the securities offered. The Company has not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.

Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.

Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Prospective investors in the rights issue should not place undue reliance on forward-looking statements. They speak only as at the date of this Presentation and the Company undertakes no obligation to update these forward-looking statements. Past performance does not guarantee or predict future performance. Moreover, the Company does not undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.

This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Swedish law. The courts of Sweden, with the District Court of Stockholm as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.



Agenda

- Scandion Oncology at a glance
- Unique technology & strong pipeline
- Growing addressable market
- Partnerships and collaboration
- Fully guaranteed rights issue





Scandion Oncology at a glance



The problem

190% of cancer deaths are related to cancer drug resistance



The solution


SCO-101 - First-in-class, unique MoA to block resistance: SRPK1 and ABCG2

- Oral formulation once daily
- Safe with limited toxicity
- Blocks resistance to chemotherapy and anti-estrogen treatment
- Chemotherapy will remain standard treatment of cancer for many years to come
- Combination with immunotherapy and chemotherapy



Overcoming chemotherapy resistance


SCO-101 has the potential to stop the progression of drug resistant cancer cells that survive chemotherapy treatment




Early stage cancer




Drug resistant cells survive chemotherapy treatment



Metastastic cancer consisting of drug resistant cancer cells





chemotherapy prevents cancer drug resistance

Drug resistant cancer cells Drug sensitive cancer cells


Note: Schematic illustration



Unique technology & strong pipeline



SCO-101 works in synergy with chemotherapy







SCO-101 in metastatic colorectal cancer

Primary efficacy end-point: Objective response rate

Part 1 Part 2

Safety, toxicity and effect (First effect measure)

Patients with metastatic and FOLFIRI resistant colorectal cancer



Dose selection

Effect (Proof-of-Concept)



25 Patients with metastatic and FOLFIRI resistant colorectal cancer¹



12-18

SCO-101 in metastatic pancreatic cancer



End-points: Safety, PFS, OS and clinical benefit rate

Part 1 Part 2

Dose range finding (safety, toxicity) and effect (First effect measure)

Dose selection


Effect (Proof-of-Concept)

12-18

Patients with metastatic pancreatic cancer (PDAC)

SCO-101 + nab-paclitaxel and gemcitabine





40 + 30 patients with metastatic PDAC


First line SCO-101 + nab-paclitaxel and gemcitabine¹

20 + 20 patients with metastatic PDAC

First line nab-paclitaxel and gemcitabine¹




Pipeline targeting 60% of currently used chemotherapies





Key milestones – SCO-101






✓

Growing addressable market




Chemotherapy: a growing and addressable market

Chemotherapy market expected to grow 12% annually during 2020-2024¹







Source: 1) Market Research Future, 2019. 2) SEER Cancer, 2020.



Partnerships and collaboration



Strategy to develop innovative first-in-class drugs





Drug screening platform

Pairs of drug sensitive and drug resistant patient derived cancer cell lines









The pipeline will be extended with drugs targeting additional resistance mechanisms



Pre-clinical studies and clinical validation trials

- Metastatic colorectal cancer
- First-line metastatic pancreatic cancer
- Metastatic breast cancer



Partnership

Licensing

Targeting partnerships and licensing agreements post clinical Phase II trials



Strategic partnerships and collaboration





Partnering

- Scandion's aim is to collaborate with a number of oncology directed pharma companies – enabling licensing fees and royalty payments
- Post clinical validation trials, the company will target partnerships with big pharma to obtain FDA and EMA approval followed by market launch

Partnerships and Licensing Agreements

Collaboration

- Agreement to explore the anti-tumor efficacy of the CD40 antibody mitazalimab (Alligator Bioscience) in combination with SCO-101 and chemotherapy in order to generate an immunological response in chemotherapy resistant preclinical tumor models
- The expectation is that SCO-101 will **revert chemotherapy resistance** and thereby further strengthen the anti-tumor effects of mitazalimab
- First results from the co-development is expected in Q2 2021

Targeting various treatment modalities enables Scandion Oncology to enter into partnerships and licensing agreements within the fields of chemotherapy-, anti-hormonal therapy-, and immunotherapy



Investment highlights



Investment highlights

Targeting cancer drug resistance

rapid peak sales can be reached given a combination therapy application

Scandion Oncology A/S is a clinical Phase II biotechnology company developing **first-in-class**, **oral**, **add-on drugs to revert resistance to existing anti-cancer therapies**.

Well-documented mechanisms of action

enabling the company to target a wide variety of cancer indications

Lead candidate, SCO-101, currently in clinical Phase II trial targeting metastatic chemotherapy resistant colorectal cancer. Data readout from part 1 in Q2 2021

A dose-range finding study targeting metastatic pancreatic cancer was initiated in October 2020

Management and Board of Directors

track record of successfully developing biotechnology companies

Proven track-record of preclinical research, clinical trials and deal activities paves the way for **future commercial success whilst reducing execution risk**



Leadership – track record of successfully developing biotechnology companies



Bo HansenPresident and CEO

- Seasoned top executive and life science entrepreneur
- Previously CEO of Genevant Sciences, Global Head & GM Roche, former executive in Santaris Pharma (acq. by Roche, USD 450m)



Nils Brünner
CSO and Co-founder

- Medical oncologist with extensive experience in cellular and molecular biology
- Previous executive positions at WntResearch and Oncology Venture
- Holdings: 1,085,370 shares



Jan Stenvang
CTO and Co-founder

- Broad experience in cancer resistance mechanisms and clinical work in several companies
- Holdings: 1,391,064 shares



Carit Andersen

- CFO
- Former CFO of AstraZeneca A/S, Denmark
- +15 years of experience in finance and biotech
- Holdings: 56,269 shares



Nicklas Roest CRO

- Broad experience in drug development spanning from preclinical to early and late stage projects
- Holdings: 26,138 shares



Peter Vestlev CMO

- Medical oncologist with experience from regulatory issues regarding cancer drugs
- Vast experience from leading clinical trials
- Holdings: 56,865 shares



Annie Rasmussen

- Extensive oncology clinical research & operational experience from Oncology Clinics & Research Units
- Co-founder of Topotarget A/S, Founder of HealthCreationDK and CancerGuidesDK
- Holdings: 3,500 shares



Peter Høngaard Andersen Chairman

- Co-founder of Acadia Pharmaceuticals, Zealand Pharma, Prexton Therapeutics (acq. by Lundbeck, USD 1,100m) Glycom (acq. by Koninklijke DSM, USD 830m), Epitherapeutics (acq. by Gilead Sciences, USD 65m
- Holdings: 39,465 shares



Carl Borrebaeck
Director

 Founder of Immunovia AB and Senzagen AB, BioInvent International AB, and Alligator BioScience AB
 Holdings: 112,165 shares



Jørgen Bardenfleth
Director

- Former CEO of Microsoft Denmark, Intel and Hewlett-Packard
- Chairman of Copenhagen Healthtech Cluster, Lyngsoe Systems A/S, Dubex A/S and Symbion A/S.
- Holdings: 458,924 shares



Thomas Feldthus
Director

 Co-founder and former CFO of Saniona AB, cofounder and former CFO of Symphogen A/S



Christian Vinding Thomsen
Director

 Specialized in law and legal issues within the pharmaceutical industry and the pharmaceutical industry in general



Annie Rasmussen
Director

 Elected employee representative of Scandion Oncology



Bo Hansen Director

 President and CEO of Scandion Oncology



Fully guaranteed rights issue



Fully guaranteed rights issue

1 existing share → 1 subscription right

2 subscription rights → 1 new share

Subscription price: 22 SEK per share

236 MSEK

Existing shares: 21,423,696



New shares in rights issue: 10,711,848



Shares post rights issue: 32,135,544

Important dates

24 November

Record date and publication of prospectus

26 November

Start of subscription period

8 December

Last day of trading in subscription rights

10 December

End of subscription period

Around 15
December

Announcement of outcome



Thank you Scandion Oncology A/S (SCOL)

Overcoming chemotherapy resistance



Contacts & Information

Scandion Oncology A/S
Fruebjergvej 3, Symbion

2100 Copenhagen, Denmark / phone: + 45 38 10 20 17

www.scandiononcology.com

For Investor Relations requests: ir@scandiononcology.com

Overcoming chemotherapy resistance

